<DOC>
	<DOCNO>NCT00001043</DOCNO>
	<brief_summary>AMENDED 8/94 : To expand safety immunogenicity profile MN rgp160 vaccine ( Immuno-AG ) administer high dose ( 800 mcg ) 0 , 1 , 6 , 12 month 0 , 2 , 8 14 month ( two schedule compare VEU 013A use dose 200 mcg ) . To obtain plasma follow fourth immunization . To evaluate skin test reactivity . ORIGINAL ( replace ) : To determine healthy volunteer safety immunogenicity two immunization MN rgp160 vaccine ( Immuno-AG ) combination live recombinant vaccinia virus LAV HIV-1 gp160 vaccine ( HIVAC-1e ) versus DryVax ( standard smallpox vaccine use many year ) control combination placebo . ORIGINAL ( replace ) : A gp160 vaccine derive MN strain , prevalent strain HIV-1 United States , develop . A previous study show combination vaccine strategy , consist prim HIVAC-1e follow boost gp160 subunit vaccine , result humoral cellular immune response great long duration either vaccine alone . Thus , live vector/subunit boost approach use MN rgp160 vaccine merit investigation .</brief_summary>
	<brief_title>A Phase I , Multicenter , Randomized Trial Evaluate Safety Immunogenicity Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein ( rgp160 ) Human Immunodeficiency Virus Two Different Vaccination Schedules</brief_title>
	<detailed_description>ORIGINAL ( replace ) : A gp160 vaccine derive MN strain , prevalent strain HIV-1 United States , develop . A previous study show combination vaccine strategy , consist prim HIVAC-1e follow boost gp160 subunit vaccine , result humoral cellular immune response great long duration either vaccine alone . Thus , live vector/subunit boost approach use MN rgp160 vaccine merit investigation . AMENDED 8/94 : Volunteers randomize receive 800 mcg MN rgp160 vaccine ( Immuno-AG ) adjuvant control ( placebo ) one two dosing schedule . Sixteen volunteer receive candidate vaccine four volunteer receive placebo . ORIGINAL ( replace ) : Volunteers randomize receive either HIVAC-1e day 0 56 follow immunization MN rgp160 vaccine day 224 364 , DryVax control day 0 56 follow placebo day 224 364 . Ten volunteer enter MN rgp160 vaccine arm two volunteer placebo arm . PER AMENDMENT 7/96 : Two additional booster immunization 600 mcg MN rgp 120/HIV-1 vaccine give study month 22 24 consent St. Louis University volunteer .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Vaccinia</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Krestin</mesh_term>
	<criteria>Inclusion Criteria Subjects must : Normal history physical exam . Negative test HIV ELISA within 6 week prior immunization . Negative test HIV Western blot . CD4 count &gt; = 400 cells/mm3 . No history smallpox vaccination . Normal urine dipstick esterase nitrate . No history immunodeficiency , chronic illness , autoimmune disease , use immunosuppresssive medication . Exclusion Criteria Coexisting Condition : Subjects follow condition exclude : Positive hepatitis B surface antigen . Medical psychiatric condition occupational responsibility preclude compliance . Active syphilis ( NOTE : If serology document false positive due remote ( &gt; 6 month ) infection , subject eligible ) . Active tuberculosis ( NOTE : Subjects positive PPD normal xray show evidence TB require INH therapy eligible ) . Eczema . Household contact person meet follow criterion : pregnancy , &lt; 12 month age , eczema , immunodeficiency disease use immunosuppressive medication . Subjects follow prior condition exclude : History anaphylaxis serious adverse reaction vaccine . Eczema within past year . PER 8/94 AMENDMENT : History cancer unless surgically excise reasonable assurance cure . PER 8/94 AMENDMENT : History serious allergic reaction require hospitalization emergent medical care . Prior Medication : Excluded : Prior HIV vaccine . Live attenuate vaccine within past 60 day . NOTE : Medically indicate subunit kill vaccine ( e.g. , influenza , pneumococcal ) exclude administer least 2 week prior HIV immunization . Experimental agent within past 30 day . Prior Treatment : Excluded : Blood product immunoglobulin within past 6 month . Higher risk behavior HIV infection determine screen questionnaire , include : History injection drug use within 12 month prior study entry . Higher intermediate risk sexual behavior .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Vaccines , Synthetic</keyword>
	<keyword>Vaccinia Virus</keyword>
	<keyword>Viral Vaccines</keyword>
	<keyword>Smallpox Vaccine</keyword>
	<keyword>HIV-1</keyword>
	<keyword>HIV Envelope Protein gp160</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
</DOC>